Abstract:Autophagy fundamentally refers to a process where cells enclose their own cell organelles with isolated membrane and deliver them to lysosomes for degradation, servicing as a nonspecific degradation mechanism of autologous proteins. Autophagy is induced above basal levels in response to nutrient deprivation or trophic factor withdrawal to sustain metabolism by producing catabolites. In this context, autophagy acts as a cytoprotective mechanism for cells to protect themselves from extracellular stresses. However, in a culture using cells in which autophagy-related genes were suppressed by siRNA and to which an autophagy inhibitor, 3- methyladenine (3-MA), was added, cytotoxic effects of some anticancer agents on cancer cells were diminished. Based on these results, the concept of caspase-independent cell death via autophagy, which is designated as type II programmed cell death (PCD) in contrast to apoptosis as type I PCD, has been receiving increased attention. We here report that treatment of AML cells with low does-Ara-C induces autophagy and enhances its cytocidal effect on AML cells by combined treatment with G-CSF. Treatment of AML cell line U937 cells with 1 to 50 ng/ml of Ara-C induced cell growth inhibition in a dose-dependent manner. Exposure to the higher concentrations of Ara-C (more than 10 ng/ml) induced apoptosis in U937 cells along with formation of apoptotic bodies and caspase-3 activation. However, treatment with the lower concentration of Ara-C (2.5 to 7.5 ng/ml) induced autophagy as assessed by electron microcopy and the punctuated distribution pattern of cytoplasmic microtubule-associated protein 1 light chain 3B (LC3B) by fluorescent immunocytochemistry. Low dose-Ara-C inducing -cell death and -autophagy both were suppressed when the cells were cultured in the presence of 3-MA. This suggests that the autophagic cell death but not the cytoprotective autophagy was induced in response to Ara-C. Combined treatment with G-CSF (lenograstim; 100 ng/ml) plus 2.5 to 7.5 ng/ml of Ara-C, but not plus higher concentrations of Ara-C, resulted in the enhanced cytocidal effect in U937 cells in vitro. These data indicate that combined treatment of Ara-C plus G-CSF has a therapeutic benefit for the AML patients by enhanced cytocidal effect which appears to be mediated via induction of autophagy. In addition, our data appear to explain in part the high response rate of CAG therapy in refractory AML, which consists of low-dose Ara-C in combination with G-CSF and aclarubicin.

[Mechanism of Apoptosis Synergistically Induced by Bortezomib Combined with Cytarabine in U937 Cell Line].

[Apoptosis in Jurkat Cells Induced by Bortezomib Combined with Adriamycin].

[Effect of Bortezomib and Low Concentration Cytarabine on Apoptosis in U937 Cell Line].

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

[Effects of Artesunate Combined with Bortezomib on Apoptosis and Autophagy of Acute Myeloid Leukemia Cells in Vitro and Its Mechanism].

Studies on the apoptosis of diffuse large B cell lymphoma cells induced by cAMP analogue combined with bortezomib

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

Arsenic Trioxide and Proteasome Inhibitor Bortezomib Synergistically Induce Apoptosis in Leukemic Cells: the Role of Protein Kinase Cδ

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia.

Synergistic Effect of Bortezomib and Valproic Acid Treatment on the Proliferation and Apoptosis of Acute Myeloid Leukemia and Myelodysplastic Syndrome Cells

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

Magnetic Nanoparticle Of Fe3o4 And 5-Bromotetrandrin Interact Synergistically To Induce Apoptosis By Daunorubicin In Leukemia Cells

Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis.

Bortezomib Induces Cell Apoptosis and Increases the Efficacy of Α PD-1 in BCR::ABL T315I Mutation CML by Targeting UBE2Q1

Autophagy Induction of Acute Myeloid Leukemia (aml) Cells after Treatment with Low Dose-Cytarabine (Ara-C) and Enhanced Cytocidal Effect on Aml Cells by Combined Treatment with Ara-C Plus Lenograstim.

[Bortezomib and Obatoclax for Dual Blockade of Protein Degradation Pathways Show Synergistic Anti-Tumor Effect in Human Acute T Lymphoblastic Leukemia Cells].

Antitumor Activity and Drug Interactions of Proteasome Inhibitor Bortezomib in Human High-Risk Myelodysplastic Syndrome Cells.

Combined Effect of Bortezomib and Homoharringtonine on K562 Cells and Their Mechanisms

Bortezomib Induces Cell Apoptosis and Increases the Efficacy of Αpd-1 in BCR::ABL T315I Mutation CML by Targeting UBE2Q1.

[Mechanism of Bortezomib in Inducing Apoptosis and Improving Chemosensitivity of Ishikawa Cells].

Synergistic Action of 5Z-7-oxozeaenol and Bortezomib in Inducing Apoptosis of Burkitt Lymphoma Cell Line Daudi